Skip to main content
Premium Trial:

Request an Annual Quote

A Journal for Bold Ideas

Researchers have rallied, sending in letters, to prevent changes to the journal Medical Hypotheses, reports The Scientist. Articles that appear in the journal are not peer-reviewed; instead, they are chosen by editor-in-chief Bruce Charlton. "Medical Hypotheses has become an important vehicle for publishing exciting new ideas and information that is helping to shape the directions of medical research," writes Paul Sherman from Cornell University. "Cancelling the journal, or massively altering its focus and editorial policies, would potentially deprive both the medical and biological communities of their only existing forum for interaction." Elsevier, which owns the journal, is considering switching it to a peer-review model after publishing a paper from an HIV denialist. Elsevier retracted that and another paper. In Times Higher Education, the University of Warwick's Steve Fuller adds: "Medical Hypotheses has never hidden what it set out to do, namely to provide a forum for bold scientific ideas that challenge the status quo."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.